Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.650–0.300 for the period, compared to the consensus earnings per share estimate of -0.790. The company issued revenue guidance of $30.1 billion-$30.4 billion, compared to the consensus revenue estimate of $30.5 billion.

Analyst Ratings Changes

Several research analysts have commented on the stock. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Morgan Stanley cut their price target on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Finally, Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $157.93.

Gilead Sciences Trading Up 3.1%

GILD stock traded up $4.12 during midday trading on Tuesday, reaching $135.27. 9,855,946 shares of the company traded hands, compared to its average volume of 7,119,565. The firm has a market capitalization of $167.95 billion, a price-to-earnings ratio of 18.43 and a beta of 0.32. Gilead Sciences has a 52-week low of $108.46 and a 52-week high of $157.29. The business has a 50 day moving average of $129.55 and a 200-day moving average of $136.03. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences will post -0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the period. Bank of America Corp DE increased its holdings in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Amundi increased its holdings in Gilead Sciences by 25.5% during the 4th quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company’s stock worth $1,168,501,000 after purchasing an additional 1,936,354 shares during the period. Charles Schwab Investment Management Inc. raised its position in Gilead Sciences by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,006,790 shares of the biopharmaceutical company’s stock valued at $982,753,000 after purchasing an additional 75,930 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its holdings in shares of Gilead Sciences by 50.6% in the 4th quarter. Raymond James Financial Inc. now owns 2,734,917 shares of the biopharmaceutical company’s stock worth $336,007,000 after buying an additional 919,106 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.